497 related articles for article (PubMed ID: 34644203)
1. Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study.
Overeem LH; Peikert A; Hofacker MD; Kamm K; Ruscheweyh R; Gendolla A; Raffaelli B; Reuter U; Neeb L
Cephalalgia; 2022 Apr; 42(4-5):291-301. PubMed ID: 34644203
[TBL] [Abstract][Full Text] [Related]
2. Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study.
Overeem LH; Lange KS; Fitzek MP; Siebert A; Steinicke M; Triller P; Hong JB; Reuter U; Raffaelli B
Front Neurol; 2023; 14():1154420. PubMed ID: 37034092
[TBL] [Abstract][Full Text] [Related]
3. Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.
Scheffler A; Messel O; Wurthmann S; Nsaka M; Kleinschnitz C; Glas M; Naegel S; Holle D
J Headache Pain; 2020 Jul; 21(1):84. PubMed ID: 32620151
[TBL] [Abstract][Full Text] [Related]
4. A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine.
Saccà F; Braca S; Sansone M; Miele A; Stornaiuolo A; De Simone R; Russo CV
Headache; 2023 Jun; 63(6):788-794. PubMed ID: 37254581
[TBL] [Abstract][Full Text] [Related]
5. Treatment Outcome After Switching From Galcanezumab to Fremanezumab in Patients With Migraine.
Youn MS; Kim N; Lee MJ; Kim M
J Clin Neurol; 2024 May; 20(3):300-305. PubMed ID: 38713076
[TBL] [Abstract][Full Text] [Related]
6. Impact of a reimbursement policy change on treatment with erenumab in migraine - a real-world experience from Germany.
Hong JB; Lange KS; Fitzek M; Overeem LH; Triller P; Siebert A; Reuter U; Raffaelli B
J Headache Pain; 2023 Oct; 24(1):144. PubMed ID: 37899428
[TBL] [Abstract][Full Text] [Related]
7. Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study.
Iannone LF; Burgalassi A; Vigani G; Tabasso G; De Cesaris F; Chiarugi A; Geppetti P
Cephalalgia; 2023 Apr; 43(4):3331024231160519. PubMed ID: 36918752
[TBL] [Abstract][Full Text] [Related]
8. An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor.
Schiano di Cola F; Bolchini M; Ceccardi G; Caratozzolo S; Liberini P; Rao R; Padovani A
Eur J Neurol; 2023 Jun; 30(6):1764-1773. PubMed ID: 36856538
[TBL] [Abstract][Full Text] [Related]
9. Initial experience with novel CGRP-receptor inhibitor therapy in Migraine in the United Arab Emirates: a retrospective observational study.
Dinh BBK; Aziz WH; Terruzzi A; Krieger DW
BMC Neurol; 2021 Dec; 21(1):486. PubMed ID: 34906111
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan.
Suzuki K; Suzuki S; Shiina T; Tatsumoto M; Fujita H; Haruyama Y; Hirata K
Cephalalgia; 2023 May; 43(5):3331024231177649. PubMed ID: 37231663
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Effect of Switching From an Anti-CGRP Receptor to an Anti-CGRP Ligand Antibody in Treatment-Refractory Chronic Migraine: A Prospective Real-World Analysis.
Lambru G; Caponnetto V; Hill B; Ratti S; Sacco S; Murphy M; Briscoe J; Andreou AP
Neurotherapeutics; 2023 Sep; 20(5):1284-1293. PubMed ID: 37430146
[TBL] [Abstract][Full Text] [Related]
12. Switching anti-CGRP monoclonal antibodies in chronic migraine: real-world observations of erenumab, fremanezumab and galcanezumab.
Talbot J; Stuckey R; Wood N; Gordon A; Crossingham G; Weatherby S
Eur J Hosp Pharm; 2024 Jan; ():. PubMed ID: 38182276
[TBL] [Abstract][Full Text] [Related]
13. CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience.
Scheffler A; Schenk H; Wurthmann S; Nsaka M; Kleinschnitz C; Glas M; Holle D
J Headache Pain; 2021 Sep; 22(1):111. PubMed ID: 34544359
[TBL] [Abstract][Full Text] [Related]
14. Characteristics associated with response to subcutaneously administered anti-CGRP monoclonal antibody medications in a real-world community cohort of persons living with migraine: A retrospective clinical and genetic study.
Chase BA; Semenov I; Rubin S; Meyers S; Mark A; Makhlouf T; Chirayil TT; Maraganore D; Wei J; Zheng SL; Xu J; Epshteyn A; Pham A; Frigerio R; Markopoulou K
Headache; 2024 Jan; 64(1):68-92. PubMed ID: 38071464
[TBL] [Abstract][Full Text] [Related]
15. Persistent effectiveness of CGRP antibody therapy in migraine and comorbid medication overuse or medication overuse headache - a retrospective real-world analysis.
Scheffler A; Basten J; Menzel L; Binz D; Becker WA; Breunung V; Schenk H; Kleinschnitz C; Nsaka M; Lindner D; Holle D
J Headache Pain; 2024 Jul; 25(1):109. PubMed ID: 38965463
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic patterns and migraine disease burden in switchers of CGRP-targeted monoclonal antibodies - insights from the German NeuroTransData registry.
Hong JB; Israel-Willner H; Peikert A; Schanbacher P; Tozzi V; Köchling M; Reuter U; Raffaelli B;
J Headache Pain; 2024 Jun; 25(1):90. PubMed ID: 38825722
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of Switching CGRP Monoclonal Antibodies in Non-Responder Patients in the UAE: A Retrospective Study.
Suliman R; Santos V; Al Qaisi I; Aldaher B; Al Fardan A; Al Barrawy H; Bader Y; Supena JL; Alejandro K; Alsaadi T
Neurol Int; 2024 Feb; 16(1):274-288. PubMed ID: 38392960
[TBL] [Abstract][Full Text] [Related]
18. Early Effect of Calcitonin Gene-related Peptide Monoclonal Antibodies in Migraine with Medication Overuse: A Single-center Retrospective Study.
Ito Y; Mitsufuji T; Okada M; Fujita S; Yokoyama R; Kawasaki H; Yamamoto T
Intern Med; 2023 Dec; 62(23):3455-3460. PubMed ID: 37062749
[TBL] [Abstract][Full Text] [Related]
19. Migraine therapeutics differentially modulate the CGRP pathway.
Bhakta M; Vuong T; Taura T; Wilson DS; Stratton JR; Mackenzie KD
Cephalalgia; 2021 Apr; 41(5):499-514. PubMed ID: 33626922
[TBL] [Abstract][Full Text] [Related]
20. Pooled retrospective analysis of 70 mg erenumab in episodic and chronic migraine: a two tertiary headache centers experience during clinical practice.
Storch P; Burow P; Möller B; Kraya T; Heintz S; Politz N; Naegel S
Acta Neurol Belg; 2022 Aug; 122(4):931-937. PubMed ID: 34406609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
